Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease

This study has been completed.
Sponsor:
Collaborator:
INC Research
Information provided by (Responsible Party):
Regenera Pharma Ltd
ClinicalTrials.gov Identifier:
NCT01513967
First received: January 17, 2012
Last updated: December 5, 2016
Last verified: June 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)